Cosmo announces proposed placement of Santarus shares in a secondary stock offering in USA Lainate, Italy - May 10, 2013 - Cosmo Pharmaceuticals, (SIX:COPN) today announced that its subsidiary Cosmo Technologies Ltd, has entered into an agreement to sell Santarus (NASDAQ:SNTS) shares in a secondary underwritten public offering. The transaction is underwritten by Jefferies LLC who is acting as sole book runner. Santarus will not sell any shares or receive any proceeds from the offering. There can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering. About Cosmo Pharmaceuticals Cosmo is a speciality pharmaceutical company that aims to become a global leader in the field of optimized therapies for selected Gastrointestinal and topically treated Skin Disorders. The company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, such as Ulcerative Colitis and Crohn's Disease, and Colon Infections. In addition, the Company is developing a diagnostic for the detection of colon cancer and a new chemical entity for the topical treatment of Acne, Alopecia and Hirsutism. Cosmo's first product in the market is Lialda/Mezavant/Mesavancol, a treatment for mild to moderate Ulcerative Colitis that is licensed globally to Giuliani and Shire Limited. Cosmo's second product is Uceris(TM)/Cortiment(TM), a steroid with low side effects that is indicated for Ulcerative Colitis patients that do not get relief when treated with 5-ASA's and is licensed globally to Santarus and Ferring. Cosmo's proprietary MMX technology is at the core of the Company's product pipeline and was developed from its expertise in formulating and manufacturing gastrointestinal drugs for international clients at its GMP (Good Manufacturing Practice) facilities in Lainate, Italy. The technology is designed to deliver active ingredients in a targeted manner in the intestines. For further information on Cosmo, please visit the Company's website: www.cosmopharma.com Contact: Cosmo Pharmaceuticals S.p.A. Dr. Chris Tanner, CFO and Head of Investor Relations Tel: +39 02 9333 7614 email@example.com Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements. Press Release (PDF) Provider Channel Contact Tensid Ltd., Switzerland newsbox.ch Provider/Channel related enquiries www.tensid.ch www.newsbox.ch firstname.lastname@example.org +41 41 763 00 50
Cosmo announces proposed placement of Santarus shares in a secon
Press spacebar to pause and continue. Press esc to stop.